The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
Age greater than or equal to 18 years old;
chronic lymphocytic leukemia diagnosis according to iwCLL criteria;
refractory and/or relapsed disease during or after venetoclax treatment;
tumor samples available.
None
Patients with chronic lymphocytic leukemia diagnosis according to iwCLL criteria and who are refractory and/or relapsed disease during or after venetoclax treatment; tumor samples available.
Cohort
Retrospective
Not listed
Frequency measurement of BCL2 gene mutations
Frequency measurement of BCL2 gene mutations in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Frequency measurement of 1q amplification
Frequency measurement of 1q amplification in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Differential expression of candidate transcripts and proteins
Differential expression of candidate transcripts and proteins (BCL2 protein family, AMP signaling pathway, energy metabolism) in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Correlation of resistance mechanisms with clinical staging
Correlation of resistance mechanisms (BCL2 mutation and 1q amplification) with clinical staging, in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Correlation of resistance mechanisms with genomic chronic lymphocytic leukemia features
Correlation of resistance mechanisms (BCL2 mutation and 1q amplification) with genomic chronic lymphocytic leukemia features, in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Click on the lead sponsor to view all of their trials.
